Literature DB >> 31135487

Cutaneous Syncytial Myoepithelioma Is Characterized by Recurrent EWSR1-PBX3 Fusions.

Vickie Y Jo1, Cristina R Antonescu2, Brendan C Dickson3, David Swanson3, Lei Zhang2, Christopher D M Fletcher1, Elizabeth G Demicco3.   

Abstract

Cutaneous syncytial myoepithelioma (CSM) is a rare but distinctive benign variant in the family of myoepithelial neoplasms of skin and soft tissue. CSM has unique morphologic and immunohistochemical features, characterized by intradermal syncytial growth of spindled, ovoid, and histiocytoid cells and consistent staining for S-100 protein and EMA, and differs from other myoepithelial tumors by showing only infrequent keratin staining. Rearrangement of the EWSR1 gene is now known to occur in up to half of all skin and soft tissue myoepithelial tumors, with a wide family of documented fusion partners. In 2013, we reported frequent (80%) EWSR1 rearrangements in CSM, but were unable to identify the fusion partner using available studies at that time. After recent identification of an index case of CSM harboring an EWSR1-PBX3 fusion, we used a combination of targeted RNA sequencing and fluorescence in situ hybridization (FISH) studies to investigate the genetic features of a cohort of CSM. An EWSR1-PBX3 fusion was identified in all 13 cases successfully tested. RNA sequencing was successful in 8/13 cases, all of which were found to have identical breakpoints fusing exon 8 of EWSR1 to exon 5 of PBX3. FISH confirmed both EWSR1 and PBX3 rearrangements in 9/9 cases tested, which included 4 confirmed to have EWSR1-PBX3 fusion by RNA-Seq, 3 cases that failed RNA-Seq, and 2 cases examined by FISH alone. Two cases failed RNA sequencing but had no additional tissue remaining for FISH studies. Our findings demonstrate that EWSR1-PBX3 fusions occur in most (and possibly all) cases of CSM.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31135487      PMCID: PMC6742566          DOI: 10.1097/PAS.0000000000001286

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  37 in total

Review 1.  PBX proteins: much more than Hox cofactors.

Authors:  Audrey Laurent; Réjane Bihan; Francis Omilli; Stéphane Deschamps; Isabelle Pellerin
Journal:  Int J Dev Biol       Date:  2008       Impact factor: 2.203

2.  PBX2 and PBX3, new homeobox genes with extensive homology to the human proto-oncogene PBX1.

Authors:  K Monica; N Galili; J Nourse; D Saltman; M L Cleary
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

3.  The human t(1;19) translocation in pre-B ALL produces multiple nuclear E2A-Pbx1 fusion proteins with differing transforming potentials.

Authors:  M P Kamps; A T Look; D Baltimore
Journal:  Genes Dev       Date:  1991-03       Impact factor: 11.361

4.  Myoepitheliomas of the skin and soft tissues. Report of 12 cases.

Authors:  M Michal; M Miettinen
Journal:  Virchows Arch       Date:  1999-05       Impact factor: 4.064

5.  Cutaneous myoepithelioma: an under-recognized cutaneous neoplasm composed of myoepithelial cells.

Authors:  H Kutzner; T Mentzel; S Kaddu; L M Soares; O P Sangueza; L Requena
Journal:  Am J Surg Pathol       Date:  2001-03       Impact factor: 6.394

6.  Myoepithelial tumors of soft tissue: a clinicopathologic and immunohistochemical study of 101 cases with evaluation of prognostic parameters.

Authors:  Jason L Hornick; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2003-09       Impact factor: 6.394

7.  Cutaneous myoepithelial neoplasms: clinicopathologic and immunohistochemical study of 20 cases suggesting a continuous spectrum ranging from benign mixed tumor of the skin to cutaneous myoepithelioma and myoepithelial carcinoma.

Authors:  Thomas Mentzel; Luis Requena; Steven Kaddu; Luis M Soares de Aleida; Omar P Sangueza; Heinz Kutzner
Journal:  J Cutan Pathol       Date:  2003-05       Impact factor: 1.587

Review 8.  Myoepithelioma of the soft tissue of the head and neck: a case report and review of the literature.

Authors:  Antonio Galvao Neto; Keyla Pineda-Daboin; Mario A Luna
Journal:  Head Neck       Date:  2004-05       Impact factor: 3.147

9.  Cutaneous myoepithelioma: a clinicopathologic and immunohistochemical study of 14 cases.

Authors:  Jason L Hornick; Christopher D M Fletcher
Journal:  Hum Pathol       Date:  2004-01       Impact factor: 3.466

10.  A case of cutaneous myoepithelial carcinoma.

Authors:  Jin Tanahashi; Kenji Kashima; Tsutomu Daa; Yoshiyuki Kondo; Eiji Kuratomi; Shigeo Yokoyama
Journal:  J Cutan Pathol       Date:  2007-08       Impact factor: 1.587

View more
  5 in total

Review 1.  Soft Tissue Special Issue: Myoepithelial Neoplasms of Soft Tissue: An Updated Review with Emphasis on Diagnostic Considerations in the Head and Neck.

Authors:  Vickie Y Jo
Journal:  Head Neck Pathol       Date:  2020-01-16

Review 2.  Epithelioid Cutaneous Mesenchymal Neoplasms: A Practical Diagnostic Approach.

Authors:  Joon Hyuk Choi; Jae Y Ro
Journal:  Diagnostics (Basel)       Date:  2020-04-17

3.  Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children's Oncology Group.

Authors:  Michael D Kinnaman; Chong Zhu; Daniel A Weiser; Sana Mohiuddin; Pooja Hingorani; Michael Roth; Jonathan Gill; Katherine A Janeway; Richard Gorlick; Stephen L Lessnick; Patrick J Grohar
Journal:  Sarcoma       Date:  2020-12-05

Review 4.  Recent Advances on Immunohistochemistry and Molecular Biology for the Diagnosis of Adnexal Sweat Gland Tumors.

Authors:  Nicolas Macagno; Pierre Sohier; Thibault Kervarrec; Daniel Pissaloux; Marie-Laure Jullie; Bernard Cribier; Maxime Battistella
Journal:  Cancers (Basel)       Date:  2022-01-18       Impact factor: 6.639

Review 5.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.